Nuclidium
Phase 1Next-generation copper-based radiopharmaceuticals enable the highest accuracy and accessibility for targeted cancer treatment
Founded
2019
Focus
Radiopharmaceuticals
About
Next-generation copper-based radiopharmaceuticals enable the highest accuracy and accessibility for targeted cancer treatment
Funding History
2Total raised: $31.3M
Series A$26MVersant VenturesJan 15, 2023
Seed$5.3MVersant VenturesOct 15, 2021
Company Info
TypePrivate
Founded2019
LocationBasel, Switzerland
StagePhase 1
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile